Shift Bioscience

Shift Bioscience is making biological-age control a reality with machine learning. Driven by the increasing toll of chronic diseases of ageing, US healthcare spending is predicted to rise from 18% to 34% of GDP by 2040. The collision of Cov19 with chronic diseases will only worsen this crisis. Therapeutics targeting the causes of ageing rather than the symptoms are urgently needed and offer the only sustainable-solution. Pluripotent ‘Yamanaka factors' have comprehensive rejuvenative properties but can induce cancer, raising concerns about therapeutic translation. Shift Bioscience is focused on discovery of safer biology for biological age control through a machine learning approach. This promises a new class of drug that removes the huge cost of ageing from society, whilst expanding frontiers of time and space for individuals.